anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a preparation technology and a production method for an integrated new formulation of a Chinese yam pill, wherein the raw materials of active ingredients comprise: 21 kinds of Chinese medicine herbs including 90 parts by weight of Chinese yam, 30 parts by weight of Chinese angelica, 6 parts by weight of Japanese ampelopsis root, 18 parts by weight of saposhnikovia root, 100 parts by weight of jujube, and the like. The production process of the Chinese yam pill comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of Chinese yam pill is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of Chinese yam pill can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of Chinese yam pill can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
Ageing is accompanied by a decline in immune function (immunosenescence), increased inflammation (inflammaging), and more senescent cells which together contribute to age-related disease and infection susceptibility. The innate immune system is the front-line defence against infection and cancer and is also involved in the removal of senescent cells, so preventing innate immunosenescence and inflammaging is vital for health in older age. Extracellular vesicles (EVs) modulate many aspects of innate immune function, including chemotaxis, anti-microbial responses, and immune regulation. Senescent cell derived EVs (SEVs) have different cargo to that of non-senescent cell derived EVs, suggesting alterations in EV cargo across the lifespan may influence innate immune function, possibly contributing to immunosenescence and inflammaging. Here we review current understanding of the potential impact of miRNAs, lipids and proteins, found in higher concentrations in SEVs, on innate immune functions and inflammation to consider whether SEVs are potential influencers of innate immunosenescence and inflammaging. Furthermore, senolytics have demonstrated an ability to return plasma EV content closer to that of non-senescent EVs, therefore the potential use of senotherapeutics (senolytics and senostatics) to ameliorate the effects of SEVs on immunosenescence and inflammaging is also considered as a possible strategy for extending health-span in older adults.
The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no. PKR activity, or as being PKR-/-, STAT1-/- or both PKR-/- and STAT1-/-. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided by prescription to be obtained at the subject's expense. This represents usual care for glaucoma in Africa and other regions of the world.
Background: A promising approach in secondary prevention of problem drinking is to provide brief interventions in medical settings. However, brief interventions have not become implemented in general practices (GPs) due to insufficient role security and therapeutic commitment of physicians. Computerized expert systems can provide very cost-effective means of intervention and have been effective in the field of smoking cessation. However, in the alcohol field, research on this issue is scarce.

Objectives: Comparing an expert system based on the Transtheoretical Model of behavior change for patients with at-risk drinking, alcohol abuse or alcohol dependence to a control condition. Methods: About 2,500 screenings among consecutive general hospital patients aged 18 to 64 will be conducted. Subjects fulfilling inclusion criteria (severe alcohol dependence excluded) will be randomly assigned to one of two conditions with 150 patients each: (1) In the TTM-based expert system group, patients receive an individualized feedback on drinking norms, health-related risks and core constructs of the TTM, augmented by a TTM-based manual. (2) In the control group, participants receive a booklet on health behavior. Outcome assessment will be conducted after 12 months. Outcome variables are alcohol consumption, stages of change progress and utilization of formal help. Expected impact: Findings are expected to provide evidence for a computerized TTM based expert system to be used in primary care. This would be the first international results confirming such an approach in the alcohol field. If a TTM-based expert system would be effective, this could significantly save resources and enhance secondary prevention. Therefore, data are of great public health interest. Relationship to the objective of the collaboration: As in the other studies, empirical data on new proactive approaches to reach underserved populations in the addiction field will be provided. The project will add knowledge on the economical use of interventions.
Caregivers in the study group were given 45 minutes of training and a booklet in line with the training booklet prepared according to daily life activities aimed at improving the patient's quality of life and reducing the caregiver's care burden. The caregivers in the study group were given the researcher's contact number and were able to reach the researcher whenever they needed.
PROBLEM TO BE SOLVED: To enable a medical clinic to easily refer to medical treatment information on an introduced patient when the patient is introduced to the medical clinic by other medical clinic. SOLUTION: Copies of electronic charts DB12, 13, etc., of each medical clinic are stored in an electronic chart DB1 of an electronic chart server 2. A file generation part 15 of an introduced patient server 1 is requested to register the medical treatment information on the introduced patient by a computer 3 at the medical clinic as an introduction origin. Corresponding medical treatment information is drawn from the electronic chart DB11 and registered in a medical treatment information file 14 of the introduced patient by adding information on the medical clinic as the introduction destination to the medical information by the file generation part 15.  When the medical treatment information on the introduced patient is referred to from a computer 4 at the medical clinic as the introduction origin, the medical treatment information file 14 on the introduced patient is retrieved, the corresponding medical treatment information is acquired and transmitted to the computer 4 at the medical clinic as the introduction destination by a file reference processing part 16. The received medical treatment information is displayed on a display by the computer 4 by the medical clinic as the introduction destination.
This invention makes public a kind of Chinese patent medicine for treating female mycotic leucorrhea, gonorrhea. It includes 8-20 weight portions of veronica, 12-30 weight portions of fruit of Chinese azalea, 30-40 weight portions of greenbrier, 15-20 weight portions of fruit of glossy privet. Fleece-flower root, leonurus, “Cao Xian”, calcined oyster shell, and “Gui Zhong” can also be added to it to increase the curative effect. Cuidium officiuala, Chinese yam, agalloch and tree peony bark can also be added to it the achieve the effect of dispelling wind and promoting blood circulation. Fox-glove and drug of solomonseal can also be added to it to further achieve the effect of tonifying “qi” and improving one's look. Summing up the pesticide effect, this invention is a Chinese patent medicine for treating female mycotic leucorrhea, gonorrhea. It can eliminate mycotic, clear away the toxin in the body, cure effectively itching, red and swollen, metro-erosion, and other diseases infected by leucorrhea, gonorrhea, thus to cue thoroughly mycotic leucorrhea, gonorrhea. Besides, the Chinese herbal medicines adopted by this invention are all commonly-seen medicines and their prices are rather low.
Robotic adrenalectomy (RA) has gained significant popularity in the management of adrenal gland diseases. We report our experience at a single tertiary institution and evaluate the safety and surgical outcomes of RA. The data of 122 consecutive patients who underwent RA from October 2009 to December 2022 at Korea University Anam Hospital (Seoul, Korea) were reviewed. There were no perioperative complications. Clinicopathological features and surgical outcomes were retrospectively analyzed through complete chart reviews. Noteworthy findings include the influence of sex, tumor size, and body mass index on operation time, with the female and small tumor groups exhibiting shorter operation times (P = 0.018 and P = 0.009, respectively). Pheochromocytoma was identified as a significant independent risk factor for a longer operation time in the multivariate analysis [odds ratio (OR), 3.709; 95% confidence interval (CI), 1.127-12.205; P = 0.031]. A temporal analysis revealed a decreasing trend in mean operation times across consecutive groups, reflecting a learning curve associated with RA adoption. RA is a safe and effective operative technique alternative to laparoscopic adrenalectomy that has favorable surgical outcomes and enhances the convenience of the operation.
Disclosed are methods of producing fusion proteins including those with dual biological activities. These methods include the provision of first and second DNA sequence encoding a first and second polypeptide, respectively, the digestion of the first DNA sequence at a restriction site adjacent its 5' terminus, and the ligation of a linker/adapter sequence (1/a) to the restricted end of the first DNA sequence, thereby forming a cassette. The 1/a includes, at one end, that portion of the first DNA sequence extending from its terminus nearest the restriction site to the restriction site, and at the other end, one side of a splice site. A eucaryotic host cell is transfected with the cassette and the second DNA sequence having, at one end, one side of a splice site compatible with the side of the splice site on the 1/a. The transfected host cell is cultured to express the transfected DNA as a single chain fusion protein. <IMAGE>
Chronic periodontitis (CP) is distinguished by an inflammatory reaction and the presence of oxidative stress (OS), which has consequences for overall health. Interleukin-1β (IL-1β) and malondialdehyde (MDA) serve as markers of inflammation and OS, respectively. Analyzing the alterations in their reaction to periodontal therapy can provide valuable insights into the management and monitoring of CP progression. The current study aimed to evaluate the impact of non-surgical periodontal therapy (NST) on IL-1β and MDA levels in the serum and saliva of CP patients and explore their correlation with clinical periodontal indices post-therapy. There were 60 participants in this research, aged 33 to 50, equally split between thirty periodontally healthy controls and 30 patients with CP. Measures were taken of the clinical periodontal parameters, including the bleeding index, probing pocket depth, gingival index, and plaque index. Saliva and blood samples were collected for IL-1β and MDA analysis using ELISA and spectrophotometrically. CP patients received scaling and root planning (SRP) as part of phase I periodontal therapy, and after six weeks, we reevaluated clinical parameters and IL-1β and MDA levels. In CP patients, both saliva and serum IL-1β and MDA levels significantly increased alongside worsening clinical periodontal parameters compared with periodontally healthy individuals. phase I periodontal therapy led to a notable decrease in both saliva and serum IL-1β and MDA levels, accompanied by improvements in clinical parameters. Additionally, following six weeks of scale and root planning treatment, our data showed a strong positive relationship between salivary IL-1β and MDA levels with PPD and CAL. SRP therapy is effective in managing periodontal health, as evidenced by a significant decrease in clinical parameters and biomarker levels after treatment for CP patients. This suggests that salivary IL-1β and MDA may be useful biomarkers for indicating the severity of periodontal disease and the effectiveness of treatment.
Arm A practices will be further randomized 1:1 into two groups (A1:A2) to observe lung cancer screening standard of care. Practices in A1 will be observed.
PROBLEM TO BE SOLVED: To obtain the subject composition excellent in conditioning ability and having low stimulating properties without spoiling washing ability by using a specific sulfosuccinic acid-based surfactant together with a specific ester of a fatty acid with a polyhydric alcohol. SOLUTION: In this detergent composition for washing hair, a sulfosuccinic acid-based surfactant expressed by formula I  R1 is an alkyl, a hydroxyalkyl, etc.; one of X1 and X2 is SO3 M2(1/m) and the other is H; A is O-(BO)n1 or CONH-(BO)n1 [(n1 ) is 0-20; B is an alkylene, etc.]; M1 and M2 are each H, an alkali metal, an alkaline earth metal, etc.; (m) is 1 or 2} and a fatty acid ester of a >=3C polyhydric alcohol are added. As the fatty acid ester of the >=3C polyhydric alcohol, a fatty acid ester of propylene glycol expressed by formula II [X3 and X4 are each COR2 (R2 is an alkyl, etc.) or H and at least one of X3 and X4 is COR2 ] is preferable. It is preferable to add about 1-30wt.% of the compound of formula I and about 0.1-5wt.% of the fatty acid ester of polyhydric alcohol each based on the whole amount of the composition.
In the present study, our aim was to firstly, validate 3 commonly used scales for use in patients with dysphagia due to malignancy, and secondly, to validate them in the Swedish language. The 3 scales were: The Watson dysphagia scale, which was developed in studies on surgical treatment of reflux disease. It consists of questions about food with 9 different viscosity and solidity and the patient answer if they have problems with a specific food: never, sometimes or always when ingesting this. The scores are added and provides a range of 0-45 where 45 is the worst possible dysphagia. The Ogilvie score is a 5-graded scale 0-4 where 4 is total inability to swallow. The Goldschmid score is graded from 0-5 where 0 is inability to swallow and 5 is normal function. QoL was measured with validated instruments originating from the European Organization for Research and Treatment of Cancer (EORTC), which has a generic instrument that measures global QoL in patients with cancer (QLQ-C30) and a more symptom-specific instrument that is developed for cancer in the oesophagus and stomach (QLQ-OG25). These are well known, validated instruments that also have normal reference values for the healthy population. The symptom specific instrument QLQ-OG25 includes a dysphagia module consisting of 3 questions which is validated to malignant disease and food intake with the help of expert groups and deep interviews with patients.
A man in his late 70s, retired and independent, generally fit and well with a history of normal cognitive function baseline presented with liver abscess and acute kidney injury. He received meropenem 1 g three times a day for 15 days then subsequently changed to ertapenem 1 g one time a day in preparation for outpatient antibiotic treatment. After 2 days of starting ertapenem, the patient developed night-time delirium, decreased orientation and insomnia, loss of appetite, jerking and hallucination. Investigations have been done to investigate the cause of acute delirium, including lumbar puncture, CT brain, MRI brain, repeat CT abdomen and pelvis to monitor the liver abscess, and electroencephalogram but results were all unremarkable. Medication history during admission was reviewed and discontinued one by one the medications that were suspected to have caused the encephalopathy. Two days following the discontinuation of ertapenem, the patient's symptoms improved with a rapid return to his baseline and without neurological deficit.
INTRODUCTION: Healthy gestational weight gain (GWG) is associated with improved pregnancy and delivery outcomes. Previous literature shows provider advice and expectations regarding GWG significantly associated with GWG outcomes. In this study, we explore the influence of these factors on GWG in a military population in this secondary analysis of data from a randomized controlled trial.
MATERIALS AND METHODS: Participants (N = 377) came from a completed randomized controlled trial focused on behavioral interventions for healthy GWG and/or postpartum weight loss among TRICARE beneficiaries. At baseline, participants filled out a 5-item questionnaire assessing provider advice and self-expectations for GWG. For the actual GWG primary outcome variable, we calculated the difference between the weight obtained in the first trimester and the weight obtained at 36 weeks of gestation. We used regression models to assess the predictive ability of expectations about GWG on actual GWG.
RESULTS: Participants with higher baseline BMIs were more likely to expect excessive GWG as defined by the National Academy of Medicine (NAM; Overweight: 46.3%, Obesity: 65.4%). Participants' expectations showed a significant association with actual GWG (OR 2.1, 95% CI 1.29-3.41, p = 0.003). Most participants (64.7%) reported no provider advice about how much weight to gain during their pregnancy. Of those who did receive advice, 55.4% reported that it was within the NAM guidelines.
CONCLUSIONS: The study documented infrequent provider advice about GWG in a large sample of TRICARE beneficiaries (i.e., both active duty and non-active duty individuals) and supported an association between self-expectations and later actual GWG. Future studies might test strategies to increase/improve provider advice regarding GWG and to aid pregnant individuals in shaping and achieving their GWG expectations.
CLINICAL TRIAL REGISTRATION: The trial was prospectively registered on clinicaltrials.gov (NCT03057808) on February 20, 2017.
CELEBREX was evaluated to reduce the number of adenomatous colorectal polyps. A randomized, double-blind, placebo-controlled study was conducted in patients with FAP. The study population included 58 patients with a prior subtotal or total colectomy and 25 patients with an intact colon. Thirteen patients had the attenuated FAP phenotype.

One area in the rectum and up to four areas in the colon were identified at baseline for specific follow-up, and polyps were counted at baseline and following six months of treatment. The mean reduction in the number of colorectal polyps was 28% for CELEBREX 400 mg twice daily, 12% for CELEBREX 100 mg twice daily and 5% for placebo. The reduction in polyps observed with CELEBREX 400 mg twice daily was statistically superior to placebo at the six-month timepoint (p=0.003). (See Figure 1)
* Solution and fluid path are sterile and non-pyrogenic if the tip cap is in place, syringe is intact and there is no evidence of leakage. Use proper aseptic technique.
  * Inspect plastic wrapping. Do not use if plastic wrapping is damaged or not intact. (Figure 1)
  * Remove plastic packaging by tearing along perforation. (Figure 2)
  * Do not use if, solution is discolored, cloudy, hazy, or contains a precipitate, or if the syringe is damaged. (Figure 3)
  * With the tip cap of the syringe on, press the syringe forward to properly activate the syringe. Improper activation may difficult syringe use and/or may cause plunger rod separation. Never draw back rod because the product may become contaminated. (Figure 4) 
  * Remove tip cap. Hold the syringe unit upright and prime to expel any air bubble if present. (Figure 5)
  * Syringe is now ready to use.
  * Use aseptic techniques for diluting or dissolving drugs, mix thoroughly and use according to the drug manufacturer’s label instructions.
  * Discard empty unit after use. Discard any unused portion. Do not reuse disposable syringes.
During the safety run-in period, the first 15 patients enrolled will be assigned to received study drug SDX-7320 plus Eribulin. Not randomized.
A microparticle formation system and methods that combine aspects of spray drying and coacervation into a single process. A temperature controllable spray head mounted on a movable stage within spray chamber produces droplets of solution having controlled size and temperature. The solution can include one or more solvents, components and active agents such as APIs. A wet sample-receiving reservoir at the bottom of the chamber holds a desired receiving solvent or solvents. The system is configurable such that the droplets do not have to be fully dry before reaching the reservoir. The first solvent may be miscible with a reservoir solvent such that conservation occurs, resulting in the formation of microparticles. Microparticles formed in this manner have a well-defined or controlled size of low polydispersity.
Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.